What is the debt of AnaptysBio this year?
AnaptysBio has a debt level of -35.97 USD this year.
AnaptysBio Debt 2024
AnaptysBio Debt
-35.97 USD
Ticker
ANAB
ISIN
US0327241065
WKN
A2AJ8C
In 2024, AnaptysBio's total debt was -35.97 USD, a -49.56% change from the -71.3 USD total debt recorded in the previous year.
AnaptysBio Aktienanalyse
What does AnaptysBio do?
AnaptysBio Inc is a biopharmaceutical company founded in 2005 and headquartered in San Diego, California. The company focuses on researching, developing, and marketing novel therapeutic antibodies for the treatment of autoimmune diseases, inflammation, and cancer. AnaptysBio has a unique business model that aims to make antibody development more efficient and cost-effective. Instead of relying on traditional methods like the hybridoma technique, the company uses its proprietary SHM-XEL technology to isolate and identify human antibodies directly from B cells. This approach allows AnaptysBio to quickly find, test, and optimize high-quality antibody candidates, resulting in significantly shorter development times and lower costs. The company has two main divisions. The first division focuses on the development of antibodies for the treatment of autoimmune diseases and inflammation. In this division, AnaptysBio has several promising antibody candidates in its pipeline, including ANB020, an antibody against the immune system protein IL-33, being developed for the treatment of asthma and other allergic diseases. ANB019, an antibody against the immune system protein IL-36R, being developed for the treatment of inflammatory skin conditions such as psoriasis and atopic dermatitis, is another promising candidate. The second division of AnaptysBio focuses on the development of antibodies for the treatment of cancer. Here, the company has formed a promising partnership with TESARO, a leading cancer therapy company. Together, they are developing an antibody called TSR-042 that targets the immune system protein PD-1 and is used for the treatment of various cancers such as lung cancer and bladder cancer. AnaptysBio also has several products on the market that are based on its proprietary SHM-XEL technology. These include Simponi (Golimumab), an antibody used for rheumatoid arthritis, Crohn's disease, and psoriasis, for which AnaptysBio developed the technology in partnership with Janssen Biotech. Over the years, AnaptysBio has received several significant awards and recognition for its innovative antibody development platforms and technologies. In 2017, the company was included in the Deloitte Technology Fast 500 list and received the Frost & Sullivan Technology Innovation Award for its SHM-XEL technology. Overall, AnaptysBio is an innovative biopharmaceutical company with a unique business model and a promising pipeline of antibody candidates for the treatment of autoimmune diseases, inflammation, and cancer. Through its proprietary technology and partnerships with other companies, AnaptysBio remains well-positioned to continue providing innovative therapeutic solutions for patients. AnaptysBio ist eines der beliebtesten Unternehmen auf Eulerpool.com.Debt Details
Understanding AnaptysBio's Debt Structure
AnaptysBio's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.
Year-to-Year Comparison
Analyzing AnaptysBio's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.
Impact on Investments
Investors pay close attention to AnaptysBio’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.
Interpreting Debt Fluctuations
Shifts in AnaptysBio’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.
Frequently Asked Questions about AnaptysBio stock
What was the debt of AnaptysBio compared to the previous year?
The debt of AnaptysBio has increased by -49.56% compared to the previous year dropped.
What are the consequences of high debt for investors in AnaptysBio?
High debt can pose a risk for investors of AnaptysBio, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.
What are the consequences of low debt for investors of AnaptysBio?
Low debt means that AnaptysBio has a strong financial position and is able to fulfill its obligations without overburdening its finances.
How does an increase in debt from AnaptysBio affect the company?
An increase in debt of AnaptysBio can adversely affect the financial condition of the company and result in a higher burden on its finances.
How does a reduction of debt of AnaptysBio affect the company?
A reduction in debt of AnaptysBio can strengthen the company's financial position and improve its ability to meet its financial obligations.
What are some factors that influence the debt of AnaptysBio?
Some factors that can influence the debt of AnaptysBio include investments, acquisitions, operating costs, and revenue development.
Why are the debts of AnaptysBio so important for investors?
The debts of AnaptysBio are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.
What strategic measures can AnaptysBio take to change the debt?
To change the debt, AnaptysBio can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.
How much dividend does AnaptysBio pay?
Over the past 12 months, AnaptysBio paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, AnaptysBio is expected to pay a dividend of 0 USD.
What is the dividend yield of AnaptysBio?
The current dividend yield of AnaptysBio is .
When does AnaptysBio pay dividends?
AnaptysBio pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of AnaptysBio?
AnaptysBio paid dividends every year for the past 0 years.
What is the dividend of AnaptysBio?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is AnaptysBio located?
AnaptysBio is assigned to the 'Health' sector.
Wann musste ich die Aktien von AnaptysBio kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of AnaptysBio from 10/4/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/4/2024.
When did AnaptysBio pay the last dividend?
The last dividend was paid out on 10/4/2024.
What was the dividend of AnaptysBio in the year 2023?
In the year 2023, AnaptysBio distributed 0 USD as dividends.
In which currency does AnaptysBio pay out the dividend?
The dividends of AnaptysBio are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von AnaptysBio
Our stock analysis for AnaptysBio Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of AnaptysBio Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
